Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Observe and Evaluate the Efficacy and Safety of Inaticabtagene Autoleucel Injection in the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia in Adults in the Real World

NCT06450067 is registered in ClinicalTrials.gov with Juventas Cell Therapy Ltd. as lead sponsor.

NCT NCT06450067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06450067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Observe and Evaluate the Efficacy and Safety of Inaticabtagene Autoleucel Injection in the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia in Adults in the Real World
Lead sponsor
Juventas Cell Therapy Ltd.
Phase
Observational
Overall status
Recruiting
Start date
June 5, 2024
Completion date
June 5, 2029
Enrollment
200 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia